1Department of Urology, Chinese PLA General Hospital, Beijing 100853, China; 2Department of Urology, Beijing Tsinghua Changgung Hospital, Tsinghua University
Abstract：Objective:To study the clinical utility of a fluorescence in situ hybridization (FISH) assay in the diagnosis of upper tract urothelial carcinoma (UTUC). Methods:Voided urine specimens from 144 patients with suspected upper tract urothelial carcinoma were analyzed by means of FISH assay. The specificity and sensitivity of FISH were analyzed on the basis of pathological diagnosis. Results:Of all the 144 patients, 101 were diagnosed as having UTUC. For FISH assay, the sensitivity was 54.5% and specificity was 93.9%. Conclusions:With its high sensitivity and excellent specificity, FISH assay may be a promising ancillary test and a reliable non-invasive approach to the diagnosis of upper tract urothelial carcinoma.
[1]Rouprêt M, Babjuk M, Compérat E, et al. European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update. Eur Urol, 2013, 63:1059-1071. [2]徐阿祥,杨素霞,孙圣坤,等.尿脱落细胞荧光原位杂交技术在尿路上皮癌诊断中的应用.临床泌尿外科杂志,2012,27(10):753-755. [3]Marín-Aguilera M, Mengual L, Ribal MJ, et al. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol, 2007,51(2):409-415. [4]穆大为,周利群,丁义,等. 应用荧光原位杂交技术检测上尿路的尿路上皮癌可显著提高诊断敏感性.北京大学学报(医学版),2010,42(4):381-385. [5]Fadl-Elmula I, Gorunova L, Mandahl N, et al. Cytogenetic analysis of upper urinary tract transitional cell carcinomas. Cancer Genet Cytogenet, 1999,115(2):123-127. [6]Akkad T, Brunner A, Pallwein L, et al. Fluorescence In Situ Hybridization for Detecting Upper Urinary Tract Tumors-A Preliminary Report. Urology, 2007,70(4): 753-757. [7]Luo B, Li W, Deng CH, et al. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet, 2009,189(2):93-97. [8]Mian C, Mazzoleni G, Vikoler S, et al. Fluorescence in situ hybridization in the diagnosis of upper urinary tract tumours. Eur Urol, 2010,58(2):288-292. [9]Xu C, Zeng Q, Hou J, et al. Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. Urology, 2011,77(3): 636-641. [10]Reid-Nicholson MD, Motiwala N, Drury SC, et al. Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue. Ann Diagn Pathol, 2011,15(1):37-45. [11]Reid-Nicholson MD, Ramalingam P, Adeagbo B, et al. The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder. Mod Pathol, 2009,22(1):119-127. [12]Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol, 2012,62(1):100-114. [13]Pieras E, Frontera G, Ruiz X, et al. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int, 2010,106(9):1319-1323. [14]Wheat JC, Weizer AZ, Wolf JS Jr, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol, 2012,30(3):252-258. [15]Youssef RF, Shariat SF, Lotan Y, et al. Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology, 2011,77(4):861-866. [16]Williamson SR, Montironi R, Lopez-Beltran A, et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol, 2010,76(2):112-126. [17]Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol, 2000,164(5):1768-1775. [18]Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol, 2002,168(5):1950-1954. [19]Schwarz S, Rechenmacher M, Filbeck T, et al. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. J Clin Pathol, 2008,61(3):272-277.
